Literature DB >> 31506273

Respiratory syncytial virus infection in adults.

Hannah H Nam1, Michael G Ison2.   

Abstract

Human respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is a negative sense, single stranded RNA virus that results in epidemics of respiratory infections that typically peak in the winter in temperate climates and during the rainy season in tropical climates. Generally, one of the two genotypes (A and B) predominates in a single season, alternating annually, although regional variation occurs. RSV is a cause of disease and death in children, older people, and immunocompromised patients, and its clinical effect on adults admitted to hospital is clarified with expanded use of multiplex molecular assays. Among adults, RSV produces a wide range of clinical symptoms including upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease. Here we discuss the latest evidence on the burden of RSV related disease in adults, especially in those with immunocompromise or other comorbidities. We review current therapeutic and prevention options, as well as those in development. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31506273     DOI: 10.1136/bmj.l5021

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  39 in total

Review 1.  Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis.

Authors:  Sofia Tejada; Raquel Martinez-Reviejo; Hanife N Karakoc; Yolanda Peña-López; Oriol Manuel; Jordi Rello
Journal:  Adv Ther       Date:  2022-07-25       Impact factor: 4.070

2.  Maternal RSV vaccine development. Where to from here?

Authors:  Ahinsa Gunatilaka; Michelle L Giles
Journal:  Hum Vaccin Immunother       Date:  2021-09-09       Impact factor: 4.526

3.  Severe Clinical Outcomes Among Adults Hospitalized With Respiratory Syncytial Virus Infections, New York City, 2017-2019.

Authors:  Connor R Goldman; William D Sieling; Luis R Alba; Raul A Silverio Francisco; Celibell Y Vargas; Angela E Barrett; Matthew Phillips; Lyn Finelli; Lisa Saiman
Journal:  Public Health Rep       Date:  2021-09-06       Impact factor: 3.117

4.  Application of MRT-qPCR for pathogen detection of lower respiratory tract infection.

Authors:  Shiyi Huang; Jiangpo Chen; Jian Wang; Yuqi Zhao; Cong Jin; Yuxiang Wang; Mengmeng Lu; Wenxuan Wang; Qingzeng Qian; Tieliang Pang
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

5.  Impact of respiratory viral infections on mortality and critical illness among hospitalized patients with chronic obstructive pulmonary disease.

Authors:  Sunita Mulpuru; Melissa K Andrew; Lingyun Ye; Todd Hatchette; Jason LeBlanc; May El-Sherif; Donna MacKinnon-Cameron; Shawn D Aaron; Gonzalo G Alvarez; Alan J Forster; Ardith Ambrose; Shelly A McNeil
Journal:  Influenza Other Respir Viruses       Date:  2022-09-07       Impact factor: 5.606

6.  Target capture sequencing reveals a monoclonal outbreak of respiratory syncytial virus B infections among adult hematologic patients.

Authors:  Claas Baier; Jiabin Huang; Kerstin Reumann; Daniela Indenbirken; Felicitas Thol; Christian Koenecke; Ella Ebadi; Albert Heim; Franz-Christoph Bange; Sibylle Haid; Thomas Pietschmann; Nicole Fischer
Journal:  Antimicrob Resist Infect Control       Date:  2022-06-21       Impact factor: 6.454

7.  Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures.

Authors:  L C Rijsbergen; M M Lamers; A D Comvalius; R W Koutstaal; D Schipper; W P Duprex; B L Haagmans; R D de Vries; R L de Swart
Journal:  mSphere       Date:  2021-05-12       Impact factor: 4.389

8.  Patient perceptions of vulnerability to recurrent respiratory tract infections and prevention strategies: a qualitative study.

Authors:  Laura Dennison; Sian Williamson; Kate Greenwell; Molly Handcock; Katherine Bradbury; Jane Vennik; Lucy Yardley; Paul Little; Adam W A Geraghty
Journal:  BMJ Open       Date:  2022-04-20       Impact factor: 3.006

9.  Asymptomatic Transmission and the Infection Fatality Risk for COVID-19: Implications for School Reopening.

Authors:  Sten H Vermund; Virginia E Pitzer
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

Review 10.  Priorities for developing respiratory syncytial virus vaccines in different target populations.

Authors:  Simon B Drysdale; Rachael S Barr; Christine S Rollier; Christopher A Green; Andrew J Pollard; Charles J Sande
Journal:  Sci Transl Med       Date:  2020-03-18       Impact factor: 19.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.